Lytix Biopharma AS
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more
Lytix Biopharma AS (LYTIX) - Total Assets
Latest total assets as of December 2025: Nkr81.52 Million NOK
Based on the latest financial reports, Lytix Biopharma AS (LYTIX) holds total assets worth Nkr81.52 Million NOK as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lytix Biopharma AS - Total Assets Trend (2017–2025)
This chart illustrates how Lytix Biopharma AS’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lytix Biopharma AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Lytix Biopharma AS's total assets of Nkr81.52 Million consist of 97.4% current assets and 2.6% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr10.60 Million | 13.0% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr2.09 Million | 2.6% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Lytix Biopharma AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lytix Biopharma AS's current assets represent 97.4% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2025, down from 74.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is cash and equivalents at 13.0% of total assets.
Lytix Biopharma AS Competitors by Total Assets
Key competitors of Lytix Biopharma AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lytix Biopharma AS - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lytix Biopharma AS generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lytix Biopharma AS is currently not profitable relative to its asset base.
Lytix Biopharma AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.28 | 3.91 | 2.56 |
| Quick Ratio | 4.28 | 3.91 | 2.56 |
| Cash Ratio | 0.57 | 3.56 | 0.00 |
| Working Capital | Nkr60.88 Million | Nkr 107.14 Million | Nkr 19.89 Million |
Lytix Biopharma AS - Advanced Valuation Insights
This section examines the relationship between Lytix Biopharma AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.51 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | -44.4% |
| Total Assets | Nkr81.52 Million |
| Market Capitalization | $32.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lytix Biopharma AS's assets below their book value (0.40 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lytix Biopharma AS's assets decreased by 44.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lytix Biopharma AS (2017–2025)
The table below shows the annual total assets of Lytix Biopharma AS from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr81.52 Million | -44.37% |
| 2024-12-31 | Nkr146.53 Million | +129.41% |
| 2023-12-31 | Nkr63.87 Million | -57.98% |
| 2022-12-31 | Nkr152.02 Million | -25.10% |
| 2021-12-31 | Nkr202.96 Million | +522.26% |
| 2020-12-31 | Nkr32.62 Million | +87.09% |
| 2019-12-31 | Nkr17.43 Million | -70.40% |
| 2018-12-31 | Nkr58.90 Million | +25.07% |
| 2017-12-31 | Nkr47.09 Million | -- |